IPO - ImmunityBio, Inc.

Form Type: 424B5

Filing Date: 2025-04-08

Corporate Action: Ipo

Type: New

Accession Number: 000119312525075804

Filing Summary: ImmunityBio, Inc. is offering 29,024,768 shares of common stock at an offering price of $2.584 per share, accompanied by warrants to purchase the same number of shares at an exercise price of $3.101, valid for five years. The offering seeks to raise approximately $75 million before expenses, aiming to fund the commercialization of their lead product ANKTIVA, along with supporting trials for bladder cancer treatments and general corporate purposes. The company recently received a J-code for ANKTIVA, which has significantly boosted its sales. The lead product was approved by the FDA in April 2024 for BCG-unresponsive NMIBC with CIS. The company plans to address critical supply shortages with its reagents. Investments are also being made into collaborative trials and a broader immunotherapy strategy. Risks including dilution, volatility of stock prices, and reliance on management for use of proceeds are highlighted.

Document Link: View Document